1 / 25

Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?. Patient Presentation. On Exam. Patient Follow-Up 8 Weeks. Case Questions. Estimated Frequency of Individuals With Familial Hypercholesterolemia. Problems in Identifying FH Patients.

tucker-webb
Download Presentation

Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Dyslipidemia Management Beyond Statins:Will PCSK9 Inhibition Trigger a Revolution?

  2. Patient Presentation

  3. On Exam

  4. Patient Follow-Up8 Weeks

  5. Case Questions

  6. Estimated Frequency of Individuals With Familial Hypercholesterolemia

  7. Problems in Identifying FH Patients

  8. Statin Myopathy is a Common Challenge in Lipid Management

  9. Statins and New-Onset Type 2 DiabetesFacts and Clinical Implications

  10. Case Questions

  11. Therapy for Statin Intolerance

  12. ODYSSEY FH I + II Alirocumab Significantly Reduced LDL-C From Baseline to Week 24 vs Placebo

  13. Safety Analysis (Pooled Data From FH I and FH II)

  14. ODYSSEY ComboAlirocumab Significantly Reduced LDL-C From Baseline to Week 25 vs Ezetimibe

  15. ODYSSEY LONG TERMAlirocumab Maintained Consistent LDL-C Reduction Over 52 Weeks

  16. Adverse Events of Special Interest

  17. Post-hoc Adjudicated Cardiovascular Events*

  18. Abbreviations

  19. Abbreviations (cont)

  20. Abbreviations (cont)

  21. References

  22. References (cont)

  23. References (cont)

  24. References (cont)

  25. References (cont)

More Related